Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 1,936 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $8.58, for a total value of $16,610.88. Following the transaction, the insider now directly owns 142,768 shares of the company's stock, valued at approximately $1,224,949.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Scholar Rock Stock Performance
NASDAQ:SRRK opened at $8.51 on Friday. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock Holding Co. has a twelve month low of $6.03 and a twelve month high of $21.17. The company has a market capitalization of $681.06 million, a P/E ratio of -4.07 and a beta of 0.82. The firm has a 50-day moving average price of $8.93 and a two-hundred day moving average price of $11.30.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.01. During the same period last year, the business earned ($0.47) earnings per share. As a group, research analysts expect that Scholar Rock Holding Co. will post -2.39 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Scholar Rock
Biden's Successor: The Radical Threat to YOUR Savings!
From Golden Crest | Ad
Kamala Harris isn't just playing politics; she's a serious threat to your financial security.
Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
>> Get Your FREE Wealth Protection Guide <<
Large investors have recently added to or reduced their stakes in the company. Swiss National Bank boosted its holdings in shares of Scholar Rock by 17.3% in the 4th quarter. Swiss National Bank now owns 98,100 shares of the company's stock valued at $1,844,000 after buying an additional 14,500 shares during the period. Amalgamated Bank lifted its holdings in shares of Scholar Rock by 15.5% during the fourth quarter. Amalgamated Bank now owns 4,869 shares of the company's stock valued at $92,000 after purchasing an additional 652 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Scholar Rock by 30.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company's stock worth $7,410,000 after acquiring an additional 91,754 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Scholar Rock by 616.8% in the fourth quarter. BNP Paribas Financial Markets now owns 48,372 shares of the company's stock worth $909,000 after buying an additional 41,624 shares during the period. Finally, Trexquant Investment LP acquired a new stake in Scholar Rock during the 4th quarter worth about $1,359,000. 91.08% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on SRRK shares. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Scholar Rock in a research report on Tuesday, June 25th. BMO Capital Markets boosted their price objective on Scholar Rock from $31.00 to $34.00 and gave the company an "outperform" rating in a report on Friday, August 9th. Finally, Wedbush reissued an "outperform" rating and issued a $23.00 price target on shares of Scholar Rock in a research report on Thursday, August 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Scholar Rock currently has a consensus rating of "Buy" and an average price target of $26.43.
Check Out Our Latest Stock Analysis on Scholar Rock
About Scholar Rock
(
Get Free Report)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
